Core Viewpoint - The article highlights the strong performance of public equity funds managed by various asset management firms in the first half of the year, particularly in sectors like AI, robotics, and innovative pharmaceuticals, with several fund managers achieving record net asset values [2][4]. Group 1: Fund Performance - In the first half of the year, the A-share market was active, with significant performances in sectors such as AI, robotics, and innovative pharmaceuticals [2]. - The net asset value of the "Oriental Red Medical Upgrade Stock Initiation A" fund managed by Jiang Qi increased by 44.55%, reaching a new high since its inception [2][4]. - Jiang Qi's fund maintained a high stock position of 90.37% as of June 30, with top holdings including Bai Li Tianheng and Kanghong Pharmaceutical [4]. Group 2: Manager Insights - Jiang Qi believes that the innovative pharmaceutical sector is entering a harvest phase, with expectations for a prolonged period of growth [5]. - Jiang Qi emphasizes the importance of technological advancements and clinical resources in accelerating the development of innovative pharmaceutical companies [5][6]. - Zhou Yun from Oriental Red Asset Management notes that the low interest rate environment and the "anti-involution" trend support a long-term bullish outlook for Chinese assets [7]. Group 3: Market Outlook - Jiang Cheng from Zhongtai Asset Management expresses a cautious optimism regarding macroeconomic conditions while advising caution at the micro level [8]. - Tian Yu from Zhongtai Asset Management remains optimistic about high-end liquor, citing business demand as a key driver despite recent market concerns [9].

随着今日早盘冲高触及25120.68点，恒生指数创出2022年以来的新高。 记者注意到，尽管恒生指数年内涨幅已达到25%，但港股市场依旧具备低估值、南下资金大幅净流入以及央国企增持等优 势。不少券商机构认为，港股市场风险偏好正进一步增强，未来仍可保持乐观。 恒指创2022年以来新高 几经多空博弈，恒生指数于本周突破25000点大关，今日盘中触及25120.68点，创下自2022年以来的新高。 | 25117.39 +123.25 +0.49% | | | 恒生指数 क्रॉन HSI | | --- | --- | --- | --- | | HSI 13:36:32 | | | 恒生系列指数 / ● + | | 跌 16家 平 6家 涨 62家 关键比率 | | | | | 全额 | 1678.83 Z | | 2022 2023 2024Q | | 成交量 | 207.93 乙 | 手利率 | | | 开盘 | 25024.93 | 净利率 | | | 貴旨 | 25123.64 | | | | 最低 | 24900.59 | Ebe | | | 三次深圳M 11.2 市净率 1.22 | | ROA | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 文/新浪财经上海站 陈秀颖 2025年上半年，中国创新药行业在政策红利与国际化突破的双重助力下迎来高光时刻，Wind数据显 示，A股创新药板块80家企业中，16家已发布中报预告。头部企业凭借技术壁垒与商业化能力实现爆发 式增长。 | 证券简称 | 预告净利润同比增长 | | 预告净利润同比增 董事长 | 总经理 | | --- | --- | --- | --- | --- | | | 上限 | 长下限 | | [交易日期] 最新 [交易日期] 最新 | | | [报告期] 今年中报 | [报告期] 今年中报 | | | | | [单位] %↓ | [单位] % | | | | 双鹭药业 | 356.24 | | 237.95 徐明波 | 徐明波 | | 全诺生物 | 332.10 | | 253.54 文永均 | 文永均 | | 步长制药 | 205.94 | | 110.88 赵涛 | #x15 | | 通化东宝 | 194.30 | | 194.30 李佳鸿 | 冷春生 | | 微芯生物 | 173.00 | | 173.00 X ...

新华财经北京7月22日电 （王媛媛）市场早盘探底回升，三大指数小幅上涨，创业板指领涨。截至午间 收盘，沪指报3568.78点，涨0.25%，成交4901亿元；深证成指报11069.57点，涨0.56%，成交6470亿 元；创业板指报2312.74点，涨0.69%，成交3026亿元。 板块方面，超级水电、钢铁、光伏设备、电池等板块涨幅居前，智谱AI、银行、游戏、软件开发等板 块跌幅居前。 盘面热点 盘面上，超级水电概念股维持强势，中国电建等多股涨停。光伏概念股再度反弹，亿晶光电涨停。固态 电池概念股表现活跃，德新科技涨停。下跌方面，银行股展开调整，厦门银行跌超3%。 个股跌多涨少，全市场超2700只个股下跌。 机构观点 富荣基金：权益市场情绪依旧高涨，上证指数一举站稳3500点。短期随着外部不确定性的逐步缓解，建 议重点关注高成长产业，如AI、机器人、创新药等。同时国内 "反内卷"政策正密集进入落地期，工信 部总工程师在国新办新闻发布会上表示，钢铁、有色金属、石化、建材等十大重点行业的稳增长工作方 案即将出台，核心重点是"调结构、优供给、淘汰落后产能"。随着细分行业供给端政策的持续发 布，"反内卷"相关的周期板 ...

Core Insights - The successful launch of the drug Lisatoclax (also known as Lishengtuo) by Ascentage Pharma marks a significant milestone in the development of Bcl-2 inhibitors, breaking a nine-year monopoly held by AbbVie in this field [3][10] - The research on the Bcl-2 target has spanned over three decades, highlighting the challenges and complexities involved in drug development [3][5] - Ascentage Pharma aims to differentiate its products from existing therapies, focusing on innovative solutions to address unmet clinical needs [4][6] Company Overview - Ascentage Pharma's Lisatoclax is the first domestically developed Bcl-2 inhibitor in China and the second globally, showcasing the company's commitment to innovation [3][10] - The company has also developed another product, Olverembatinib (brand name: Nairike), which took 13 years to develop, further emphasizing its long-term investment in research [3] - The CEO of Ascentage Pharma, Yang Dajun, emphasizes the importance of targeting difficult drug targets and conducting rigorous clinical designs to achieve superior drug efficacy [4][6] Clinical Development - The Bcl-2 target is likened to PD-1 in blood cancer treatment, with the potential to treat various B-cell tumors effectively [5][6] - Lisatoclax has a unique dosing regimen that allows for a rapid escalation to the target dose, which is crucial for minimizing severe side effects like Tumor Lysis Syndrome (TLS) [6][7] - Clinical data suggest that Lisatoclax has a lower incidence of TLS compared to its competitors, enhancing its safety profile and making it a more convenient treatment option [6][7] Market Position and Strategy - Ascentage Pharma's stock has seen significant growth, with a year-to-date increase of over 70% in Hong Kong and more than 120% in the US market, indicating strong investor confidence [12] - The company aims to navigate the competitive landscape of innovative drugs by focusing on unique therapeutic targets rather than following trends in the market [12][13] - Yang Dajun believes that the current wave of innovation in the pharmaceutical industry is a result of accumulated experience, technological breakthroughs, and supportive policies [10][11] Future Outlook - Ascentage Pharma is optimistic about achieving profitability by 2027, reflecting its strategic focus on developing proprietary products that can generate revenue [13] - The company is positioned to capitalize on the evolving landscape of the biopharmaceutical industry, where the distinction between biotech and large pharmaceutical companies is increasingly defined by the ability to generate profits from self-developed products [13]

Core Viewpoint - The latest FOF (Fund of Funds) report indicates that bond funds remain the primary focus for FOF managers, accounting for over half of their holdings, with a notable increase in ETF products being favored for investment [2][4]. Group 1: FOF Holdings Overview - As of the end of Q2 2025, the top five funds held by FOFs include Hai Fu Tong Zhong Zheng Short Bond ETF, Bosera Zhong Dai 0-3 Year National Development Bank ETF, Bosera Credit Selection E, Hua An Gold ETF, and Hua Xia Hang Seng ETF [2][4]. - The total number of bond funds in the top 50 held by FOFs reached 30, representing over 50% of the total [4]. - Hai Fu Tong Zhong Zheng Short Bond ETF had a market value held by FOFs exceeding 1.643 billion yuan, making it the highest valued fund among FOF holdings [4][5]. Group 2: Active Equity Fund Holdings - The top active equity fund held by FOFs is Yi Fang Da Ke Rong, with a total holding value of 384 million yuan, followed closely by Yi Fang Da Information Industry Selection C at 371 million yuan [8][9]. - Other notable active equity funds include Xing Quan Business Model Selection A and Yi Fang Da Supply Side Reform, both exceeding 300 million yuan in holdings [8][9]. Group 3: Fund Increases - The fund with the highest increase in holdings during Q2 was Bosera Credit Selection E, which saw an increase of 936 million yuan, bringing its total holding value to 1.016 billion yuan [10]. - Other funds with significant increases include Bosera An Yue Short Bond A and Bosera Credit Bond Pure Bond B, with increases of 760 million yuan and 711 million yuan, respectively [10]. Group 4: Market Outlook and Strategy - FOF managers express confidence in the A-share market, aiming for diversified and multi-strategy asset allocation [12][14]. - The focus is on sectors such as new materials, resource industries, and innovative pharmaceuticals, with a keen eye on the potential recovery of the A-share market [13][14].

Group 1: Key Recommendations - Nvidia has resumed sales of its H20 chips to China, which is expected to alleviate the domestic market's computing power shortage in the short term. AMD has also resumed sales of its MI308 chips to China. The long-term trend indicates a push towards self-sufficiency in AI chip development in China [6][7] - TSMC reported Q2 2025 revenue exceeding $30 billion, with a year-on-year growth of 44.4% and a net profit increase of 60.7%. The revenue from 7nm and below process nodes accounted for 74% of total revenue, with high-performance computing revenue growing by 14% quarter-on-quarter [8] - Global smartphone shipments grew by 1% year-on-year in Q2 2025, while shipments in China declined by 4%. The overall demand in the electronics sector is in a phase of mild recovery, with a focus on AIOT, AI-driven technologies, and consumer electronics [10][11] Group 2: Industry Insights - The Ministry of Industry and Information Technology is set to introduce a growth stabilization plan for key industries such as steel, non-ferrous metals, and petrochemicals, which may positively impact the chemical industry [13] - A fire at Covestro's plant in Germany has disrupted TDI supply, leading to price increases. The TDI price is expected to rise due to supply constraints from Covestro, maintenance in Asia, and increased overseas demand [14][15] - The pharmaceutical and biotechnology sector saw a 4% increase last week, outperforming the broader market. The 11th batch of national drug procurement has been initiated, focusing on mature drugs, which may enhance the industry's growth prospects [20][21]

AI基金上银医疗健康混合A（011288）披露2025年二季报，第二季度基金利润1359.41万元，加权平均基金份额本期利润0.0897元。报告期内，基金净值增长 率为14.18%，截至二季度末，基金规模为1.07亿元。 该基金属于偏股混合型基金，长期投资于医药医疗股票。截至7月21日，单位净值为0.834元。基金经理是杨建楠。 基金管理人在二季报中表示，报告期内，医药板块在所有板块中涨幅位列约前 1/3。在这样的背景下，我们坚持用合理价格买入优质公司，择优挑选契合产 业趋势、业绩增速和估值较为匹配的企业。二季度我们保持了对创新药、部分高值耗材、医疗服务（科学服务上游和 AI）等子板块的配置。在四月初，医 药板块在创新药的带动下，走出了较为不错的行情，主要原因是中国创新药"DEEPSEEK"时刻已至，正在从国内走向全球，开启新周期。 截至6月30日，基金近三年夏普比率为0.1767，位于同类可比基金35/105。 截至7月21日，上银医疗健康混合A近三个月复权单位净值增长率为28.23%，位于同类可比基金53/138；近半年复权单位净值增长率为49.20%，位于同类可 比基金52/138；近一年复权单位净值增 ...

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF (嘉实) showed an intraday turnover of 18.19%, with a transaction volume of 40.9491 million yuan, indicating active market trading [3] - Over the past week, the Kexin Pharmaceutical ETF (嘉实) experienced a scale increase of 16.9597 million yuan, ranking first among comparable funds [3] - The Kexin Pharmaceutical ETF (嘉实) saw a share increase of 7.5 million shares over the past week, also ranking first among comparable funds [3] - As of July 21, the Kexin Pharmaceutical ETF (嘉实) has achieved a net value increase of 43.45% over the past year, placing it in the top 16.56% among 2,929 index equity funds [3] Group 2: Stock Performance - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading stocks including 联影医疗 (9.73%), 百济神州 (6.04%), and 惠泰医疗 (5.69%) [5][3] - The highest monthly return since inception for the Kexin Pharmaceutical ETF (嘉实) was 23.29%, with the longest consecutive monthly increase being 5 months and an average monthly return of 7.43% [3] Group 3: Market Trends - Huazhong Securities maintains a bottom-up view of the pharmaceutical sector, emphasizing the importance of hard technology innovations, particularly in innovative drugs and devices, which are becoming market hotspots [6] - The recent announcement from the Shanghai Sunshine Pharmaceutical Procurement Network regarding the 11th batch of national centralized procurement includes 55 drug varieties, with key principles focusing on stability, quality assurance, and anti-competitive practices [5]

Market Performance - On July 21, the Hang Seng Index rose by 168 points or 0.7%, closing at 24,944 points, reaching a year-to-date high of 25,010 points[1] - The Hang Seng Tech Index increased by 0.8%, closing at 5,585 points, confirming an upward breakout from the range since May[1] - Market turnover increased to over HKD 263 billion, with net inflow from the Hong Kong Stock Connect at HKD 7.05 billion[1] Sector Highlights - The insurance, brokerage, oil, coal, non-ferrous metals, food and beverage, and power sectors performed strongly[1] - The launch of the Yarlung Tsangpo River hydropower project, with a total investment of approximately RMB 1.2 trillion, boosted investor sentiment in related sectors[2] - Shares of Huaxin Cement surged by 85.6%, while leading companies like Conch Cement and China National Building Material rose by 9.0% and 12.6%, respectively[1] Economic Outlook - The hydropower project is expected to directly boost fixed asset investment growth through the cement, engineering machinery, and power equipment sectors, potentially offsetting weaknesses in real estate[2] - The project is anticipated to benefit related stocks over the next decade, as current valuations are considered low[2] Real Estate Market - New home transaction volume in 30 major cities fell by 21.7% year-on-year, with a total of 1.23 million square meters sold[3] - The decline is an improvement from the previous week's 24.9% drop, with a week-on-week decrease of 5.3%[3] AI Sector Developments - UBTECH Robotics won a procurement project in Shanghai worth approximately RMB 90 million, marking the largest disclosed order in the industry[3] - The stock price of UBTECH rose by 5.2% to a one-month high following the announcement[3] Healthcare Sector Insights - The Hang Seng Healthcare Index fell by 1.2%, seen as a normal correction after recent gains[4] - The National Healthcare Security Administration is promoting a comprehensive value assessment for innovative drugs and devices, which is expected to benefit high-value clinical innovations[4]